Jazz Pharmaceuticals plc — Director's Dealing 2020

May 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-05-26

Reporting Person: Mulligan Seamus (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-26	Ordinary Shares	P	15000	$110.6498	Acquired	1117788	Direct
2020-05-27	Ordinary Shares	P	5243	$109.5516	Acquired	1123031	Direct
2020-05-27	Ordinary Shares	P	8391	$110.5174	Acquired	1131422	Direct
2020-05-27	Ordinary Shares	P	9884	$111.5623	Acquired	1141306	Direct
2020-05-27	Ordinary Shares	P	11482	$112.3189	Acquired	1152788	Direct

Footnotes

F1: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $110.1800 to $110.9800. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F2: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $109.0300 to $110.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F3: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from 110.0300 to $111.0100. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F4: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $111.0350 to $112.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F5: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $112.0500 to $112.6600. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.